Samsung BiologicsLtd Balance Sheet Health
Financial Health criteria checks 6/6
Samsung BiologicsLtd has a total shareholder equity of ₩9,830.5B and total debt of ₩1,627.7B, which brings its debt-to-equity ratio to 16.6%. Its total assets and total liabilities are ₩16,046.2B and ₩6,215.7B respectively. Samsung BiologicsLtd's EBIT is ₩1,113.7B making its interest coverage ratio -79.2. It has cash and short-term investments of ₩2,056.3B.
Key information
16.6%
Debt to equity ratio
₩1.63t
Debt
| Interest coverage ratio | -79.2x |
| Cash | ₩2.06t |
| Equity | ₩9.83t |
| Total liabilities | ₩6.22t |
| Total assets | ₩16.05t |
Recent financial health updates
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18
Recent updates
What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You
Apr 14
With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting
Mar 01These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?
Dec 28How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?
Dec 08Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?
Nov 18Financial Position Analysis
Short Term Liabilities: A207940's short term assets (₩5,522.0B) exceed its short term liabilities (₩4,157.9B).
Long Term Liabilities: A207940's short term assets (₩5,522.0B) exceed its long term liabilities (₩2,057.8B).
Debt to Equity History and Analysis
Debt Level: A207940 has more cash than its total debt.
Reducing Debt: A207940's debt to equity ratio has reduced from 21% to 16.6% over the past 5 years.
Debt Coverage: A207940's debt is well covered by operating cash flow (102.4%).
Interest Coverage: A207940 earns more interest than it pays, so coverage of interest payments is not a concern.